- Home
- AKTX vs ORKT Comparison
AKTX vs ORKT Comparison
Compare AKTX & ORKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- ORKT
- Stock Information
- Founded
- AKTX N/A
- ORKT 2003
- Country
- AKTX United States
- ORKT Singapore
- Employees
- AKTX N/A
- ORKT N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- ORKT
- Sector
- AKTX Health Care
- ORKT
- Exchange
- AKTX Nasdaq
- ORKT NYSE
- Market Cap
- AKTX 37.6M
- ORKT N/A
- IPO Year
- AKTX N/A
- ORKT 2024
- Fundamental
- Price
- AKTX $1.12
- ORKT $0.68
- Analyst Decision
- AKTX
- ORKT Strong Buy
- Analyst Count
- AKTX 0
- ORKT 1
- Target Price
- AKTX N/A
- ORKT $5.00
- AVG Volume (30 Days)
- AKTX 27.4K
- ORKT 272.2K
- Earning Date
- AKTX 08-18-2025
- ORKT 01-01-0001
- Dividend Yield
- AKTX N/A
- ORKT N/A
- EPS Growth
- AKTX N/A
- ORKT N/A
- EPS
- AKTX N/A
- ORKT N/A
- Revenue
- AKTX N/A
- ORKT $2,962,282.00
- Revenue This Year
- AKTX N/A
- ORKT $9.63
- Revenue Next Year
- AKTX N/A
- ORKT N/A
- P/E Ratio
- AKTX N/A
- ORKT N/A
- Revenue Growth
- AKTX N/A
- ORKT N/A
- 52 Week Low
- AKTX $0.85
- ORKT $0.40
- 52 Week High
- AKTX $4.40
- ORKT $8.00
- Technical
- Relative Strength Index (RSI)
- AKTX 40.86
- ORKT N/A
- Support Level
- AKTX $1.11
- ORKT N/A
- Resistance Level
- AKTX $1.18
- ORKT N/A
- Average True Range (ATR)
- AKTX 0.05
- ORKT 0.00
- MACD
- AKTX -0.00
- ORKT 0.00
- Stochastic Oscillator
- AKTX 22.48
- ORKT 0.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.